Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss / MedCity

People who come off slimming jabs regain weight four times faster than dieters

2 months / bbc

Lack of support for people on weight loss drugs leaves them vulnerable to nutritional deficiencies, say experts

2 months / medicalxpress

Poll shows most Americans want to slim down

2 months / medicalxpress

In the UK, 1.6 million adults used weight loss drugs in the past year

2 months / medicalxpress

J.P. Morgan Report: Obesity & Diabetes Dealmaking Set a New Record in 2025

2 months / medcitynews / Frank Vinluan

Weight regain seems to occur within 2 years of stopping obesity drugs

2 months / newscientist

Stopping weight loss drugs linked to weight regain and reversal of heart health markers

2 months / medicalxpress

Ochsner launches program to cut GLP-1 costs

2 months / beckershospitalreview / Ella Jeffries

Ozempic, Wegovy might lower colon cancer risk

2 months / medicalxpress

The GLP-1 Revolution: Medical Aesthetics And The Coming Battle For Control

2 months / medcitynews / Chris Plance

The Weight Loss Market in 2026: 3 Questions That Will Shape the Next Decade

2 months / medcitynews / Shantanu Gaur

MASLD as a complication of obesity must include liver risk stratification

2 months / nature / Mary E. Rinella

Clarification of evidence selection for the framework for the pharmacological treatment of obesity and its complications from the EASO

2 months / nature / Andreea Ciudin

Novo Nordisk launches daily weight-loss pill to expand GLP-1 access

2 months / medicalxpress

Lilly goes back to Nimbus for an oral obesity drug in $55M deal

2 months / endpoints / Kyle LaHucik

Arrowhead’s RNAi obesity programs head to Phase 2 after encouraging early data

2 months / endpoints / Elizabeth Cairns

Older Americans Quit Weight-Loss Drugs in Droves

2 months / kffhealthnews / Paula Span

What is 'oatzempic'? Does it actually work for weight loss?

2 months / medicalxpress

Wegovy pill hits market at $299 per month

2 months / beckershospitalreview / Paige Twenter

GLP-1 drugs might help quell sleep apnea, study suggests

2 months / medicalxpress

Semaglutide may lower burden of hospitalizations in high-risk patients

2 months / medicalxpress

Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash

2 months / endpoints / Elizabeth Cairns

PHTI: How Employers Can Manage GLP-1 Coverage

2 months / medcitynews / Marissa Plescia

What if Less Can Be More? A New Approach to GLP-1 Weight Loss Medications

2 months / medcitynews / Myra Ahmad

The expanding landscape of GLP-1 medicines

2 months / nature / Daniel J. Drucker

Multi-omic definition of metabolic obesity through adipose tissue–microbiome interactions

2 months / nature / Rima M. Chakaroun

What's ahead for the weight-loss drugs known as GLP-1s in 2026

2 months / npr / Sydney Lupkin

6 recent updates on GLP-1 drugs

2 months / beckershospitalreview / Ella Jeffries

CMS unveils Medicare coverage model for weight loss drugs

2 months / endpoints / Alexis Kramer

Brian Slomovitz: GLP-1 Receptor Agonists Are Changing the World

2 months / oncodaily

Toufic Kachaamy: A Major Shift in Obesity Treatment Just Happened

2 months / oncodaily

CMS launching payment model to boost access to GLP-1s in Medicaid, Part D

2 months / fiercehealthcare

CMS shares GLP-1 model: 7 notes

2 months / beckershospitalreview / Elizabeth Casolo

Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss

2 months / medcitynews / Frank Vinluan

Novo Nordisk says US approves first GLP-1 pill for weight loss

2 months / medicalxpress

Novo Nordisk eyes a strong launch with FDA approval of obesity pill

2 months / endpoints / Elizabeth Cairns

Obesity

Novo Nordisk and Hims bury the hatchet and carve a deal (2 days)

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (8 days)

GLP‑1 drugs associated with lower addiction risk in large study (10 days)

more #obesity

Healthcare

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (16 hrs)

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (19 hrs)

more #healthcare

Pharmaceuticals

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (20 hrs)

FDA approves leucovorin for rare folate disorder despite autism hype (32 hrs)

more #pharmaceuticals